General information

Selection criteria

Cohorts

Expansion cohort: stage III

Collaboration

Available compounds per May 2022

Drug Target genes
Abemaciclib CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR
Alectinib ALK
Alpelisib PIK3CA, PIK3R1/2, PTEN, AKT, TSC1/2
Atezolizumab + bevacizumab TMB-H / HML – ≥ 16 mut/Mb
Axitinib KDR, FLT4
Crizotinib ALK, MET, MST1R, ROS1
Dabrafenib BRAF V600
Dabrafenib + trametinib BRAF V600
Dacomitinib EGFR, HER2, HER4
Erdafitinib FGFR1, FGFR2, FGFR3, FGFR4 amplifications
Erlotinib EGFR
Entrectinib ROS1
Lenvatinib FGFR1, FGFR2, FGFR3, FGFR4
Lorlatinib ALK, ROS1
Nilotinib KIT, ABL1, PDGFRa, PDGFRb
Nivolumab MSI-H
Nivolumab + ipilimumab HML: > 199 and < 1000
TMB-H: 15 – 39 (TSO500) or 11 – 24 (Oncomine pane)
Olaparib ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L
Panitumumab RAF/RAS wildtype
Pembrolizumab HML
Regorafenib RET, KIT, FLT1, BRAF
Rucaparib BRCA1, BRCA2, RAD51C, RAD51D, PALB2
Sunitinib CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET
Talazoparib ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, PRA1, HRD signature
Trametinib MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1 (only gliomas)
Trastuzumab + pertuzumab HER2
Vemurafenib + cobimetinib BRAF
Vismodegib PTCH1
Drug  Tumor type Target Status
Abemaciclib Esophageal CCND3 amp Open
Abemaciclib Glioblastoma CDK4 amp Open
Abemaciclib HNSCC CCND1 amp Open
Abemaciclib Melanoma CCND1 amp Open
Abemaciclib NSCLC CCND1 amp Open
Abemaciclib Ovarian CCND1 amp Open
Abemaciclib Prostate CCND1 amp Open
Abemaciclib Sarcoma CDK4 amp Open
Abemaciclib SCC bladder CCND1 amp Open
Abemaciclib Urachal cancer CCND1 amp Open
Abemaciclib Carcinoma of the small intestine CCND3amp Open
Abemaciclib Carcinoma of the small intestine CDK4 amp Open
Abemaciclib Urinary tract CCND1 amp Open
Afatinib NSCLC NRG1 fusion Closed
Alectinib Tumor-agnostic ALK fusion Open
Alectinib Tumor-agnostic ALK mut/amp Open
Alpelisib Tumor-agnostic Double hit Open
Alpelisib Anal cancer PIK3R2 mut Open
Alpelisib Gynaecological tumors AKT1 mut Open
Alpelisib Gynaecological tumors PTEN loss Open
Alpelisib Gynaecological tumors PIK3R1 mut Open
Alpelisib Gynaecological SCC PIK3CA mut Open
Alpelisib Gynaecological PCC PIK3CA mut Open
Alpelisib HNSCC PIK3Ca mut Open
Alpelisib Miscellaneous tumors PIK3CA mut Open
Alpelisib NEC cervical PTEN loss Open
Alpelisib Prostate PIK3CA mut Open
Alpelisib Prostate PTEN loss Open
Alpelisib Renal cell PTEN loss Open
Alpelisib Salivary gland PTEN loss Open
Alpelisib Upper-GI PIK3CA mut Open
Alpelisib Folliculair schildkliercarcinoom PTEN loss Open
Atezolizumab + bevacizumab Tumor-agnostic TMB ≥16 mut/Mb  Open
Axitinib CRC FLT1 amp Closed
Cabozantinib Esophageal MET mut Closed
Cabozantinib GIST NTRK2 mut Closed
Cabozantinib Melanoma MET amp Closed
Cabozantinib NSCLC Ret fusion Closed
Cabozantinib Esophageal RET mut Closed
Cabozantinib NSCLC MET mut Closed
Cabozantinib Teratoma MET amp Closed
Crizotinib ACUP ALK fusion Open
Crizotinib Biliary tract ALK mut Open
Crizotinib Colorectal ALK mut Open
Crizotinib Colorectal MET amp Open
Crizotinib Esophageal MET amp Open
Crizotinib Gastric MET amp Open
Crizotinib Inflammatory myofibrlastic tumor ALK fusion Open
Crizotinib Hepatocellular MET amp Open
Crizotinib NSCLC MET amp Open
Crizotinib NSCLC MET mut On hold
Crizotinib T cell lymphoma ALK mut Open
Crizotinib Thyroid ALK mut Open
Crizotinib Thyroid MET fusion Open
Crizotinib Ovarian MET amp Open
Crizotinib Sarcoma ALK Open
Crizotinib Renal cell MET mut Open
Dabrafenib Glioblastoma BRAF V600 mut Open
Dabrafenib Urinary tract BRAF V600 mut Open
Dabrafenib + trametinib Biliary tract BRAF V600 mut Open
Dabrafenib + trametinib GIST BRAF V600 mut Open
Dabrafenib + trametinib Glioblastoma BRAF V600 mut Open
Dabrafenib + trametinib Glioma (grade 3) BRAF V600 mut Open
Dabrafenib + trametinib Low grade glioma BRAF V600 mut Open
Dabrafenib + trametinib Mamma BRAF V600 mut Open
Dabrafenib + trametinib Neuroendocrine carcinoma colon BRAF V600 mut Open
Dabrafenib + trametinib NSCLC BRAF V600 mut Closed
Dacomitinib Breast HER2 mut Open
Dacomitinib Cervix HER2 mut Open
Dacomitinib Colorectal EGFR amp Open
Dacomitinib Colorectal HER2 amp Open
Dacomitinib Endometrial HER2 amp Open
Dacomitinib Endometrial HER2 mut Open
Dacomitinib Esophageal HER2 amp Open
Dacomitinib Gastro-esophageal junction HER2 amp Open
Dacomitinib Penile HER2 fusion Open
Dacomitinib Penile EGFR amp Open
Dacomitinib Urinary tract EGFR amp Open
Durvalumab Tumor-agnostic MSI Closed
Erdafitinib Breast FGFR1amp Open
Erlotinib CRC EGFR mut Open
Erlotinib GBM EGFR fusion Open
Erlotinib GBM EGFR mut Open
Lenvatinib Adenoid cystic carcinoma FGFR2 mut Open
Lenvatinib ACUP FGFR2 fusion Open
Lenvatinib Anal cancer FGFR3 mut Open
Lenvatinib Anaplastic thyroid FGFR3 mut Open
Lenvatinib Biliary tract FGFR2 fusion Open
Lenvatinib Biliary tract FGFR3 fusion Open
Lenvatinib Biliary tract FGFR2 mut Open
Lenvatinib Biliary tract FGFR3 mut Open
Lenvatinib Cervix FGFR3 mut Open
Lenvatinib Colorectal FGFR1 amp Open
Lenvatinib Colorectal FGFR2 amp Open
Lenvatinib Endometrium FGFR2 mut Open
Lenvatinib Endometrium FGFR3 amp Open
Lenvatinib Esophageal FGFR2 amp Open
Lenvatinib Glioblastoma FGFR3 fusion Open
Lenvatinib Glioneural tumor FGFR1 mut Open
Lenvatinib Glioma FGFR1 mut Open
Lenvatinib HNSCC FGFR3 mut Open
Lenvatinib Mamma FGFR1 amp Open
Lenvatinib Mamma FGFR2 amp/mut Open
Lenvatinib Neuroendocrine nasal cavity FGFR3 amp Open
Lenvatinib NSCLC FGFR1 amp Open
Lenvatinib NSCLC FGFR2 amp Open
Lenvatinib NSCLC FGFR3 fusion Open
Lenvatinib Osteosarcoma FGFR1 amp Open
Lenvatinib Pancreas FGFR1 amp Open
Lenvatinib Pancreas FGFR2 fusion Open
Lenvatinib Papillary  cancer FGFR2 mut Open
Lenvatinib Salivary gland FGFR3 amp Open
Lenvatinib Salivary duct FGFR2 mut Open
Lenvatinib Urachal cancer FGFR2 amp Open
Lenvatinib Urinary  tract FGFR3 mut Open
Lenvatinib Vagina FGFR3 mut Open
Lorlatinib NSCLC ROS1 fusion Open
Nilotinib Colorectal PDGFRB amp Open
Nilotinib Germ cell KIT mut Open
Nilotinib GIST KIT mut Open
Nilotinib GIST PDGFRA mut Open
Nilotinib Melanoma KIT mut Open
Nilotinib Mesothelioma PDGFRA mut Open
Nivolumab Tumor-agnostic MSI (2nd stage) Closed
Nivolumab Tumor-agnostic MSI (3rd stage) On hold
Nivolumab Tumor-agnostic HML >450 Closed
Nivolumab + ipilimumab Tumor-agnostic HML 200-1000 Open
Olaparib Tumor-agnostic BRCA mut/loss Closed
Olaparib Tumor-agnostic ATM mut/loss Open
Olaparib Tumor-agnostic HRR alterations (breast, ovarian, prostate, pancreas, SCLC or stomach carcinoma) Open
Olaparib Tumor-agnostic HRR alterations (all other tumor types) Open
Panitumumab ACUP BRAF-KRAS-NRAS wildtype Open
Panitumumab Anal cancer BRAF-KRAS-NRAS wildtype Open
Panitumumab Cervix BRAF-KRAS-NRAS wildtype Open
Panitumumab Endometrium BRAF-KRAS-NRAS wildtype Open
Panitumumab Glioblastoma BRAF-KRAS-NRAS wildtype On hold
Panitumumab Gynaecological SCC BRAF-KRAS-NRAS wildtype Open
Panitumumab HNSCC BRAF-KRAS-NRAS wildtype Open
Panitumumab Meningioma BRAF-KRAS-NRAS wildtype Open
Panitumumab (uvual) melanoma BRAF-KRAS-NRAS wildtype Open
Panitumumab NSCLC BRAF-KRAS-NRAS wildtype + EGFR mut/amp Open
Panitumumab Salivary duct BRAF-KRAS-NRAS wildtype Open
Panitumumab Sarcoma BRAF-KRAS-NRAS wildtype Open
Panitumumab Thyroid BRAF-KRAS-NRAS wildtype Open
Palbociclib Astrocytoma CDK4 amp Closed
Palbociclib Biliary tract CDKN2A loss/mut Closed
Palbociclib Colorectal CCND2 amp Closed
Palbociclib Colorectal CDKN2A loss/mut Closed
Palbociclib Colorectal SMARCA4 mut Closed
Palbociclib Duodenal CDKN2A loss/mut Closed
Palbociclib Endometrial carcinoma CDKN2A loss/mut Closed
Palbociclib Esophageal CDK4 amp Closed
Palbociclib Esophageal CDKN2A loss/mut Closed
Palbociclib Glioblastoma CDKN2A loss/mut Closed
Palbociclib HNSCC CDKN2A loss/mut Closed
Palbociclib Melanoma CCND1 amp Closed
Palbociclib Melanoma CDKN2A loss/mut Closed
Palbociclib Neuroendocrine tumor CDKN2A loss/mut Closed
Palbociclib Neuroendocrine tumor CCND1 amp Closed
Palbociclib NSCLC CCND1 amp Closed
Palbociclib NSCLC CDKN2A loss/mut Closed
Palbociclib (uvual) melanoma CDKN2A loss/mut Closed
Palbociclib Ovarian CDKN2A loss/mut Closed
Palbociclib Ovarian SMARCA4 mut Closed
Palbociclib Pancreas CDKN2A loss/mut Closed
Palbociclib PECoom CDK4 amp Closed
Palbociclib Primitive Neuro-ectodermal tumor CDKN2A loss/mut Closed
Palbociclib Prostate CDK4 amp Closed
Palbociclib Prostate CDK6 amp Closed
Palbociclib Renal cell CDKN2A loss/mut Closed
Palbociclib Sarcoma CDK4 amp Closed
Palbociclib Vulva carcinoma CDKN2A loss/mut Closed
Palbociclib Vulva carcinoma CCND1 amp Closed
Pembrolizumab Colorectal HML 140-290 Closed
Pembrolizumab HNSCC HML 140-290 Open
Pembrolizumab Mamma HML 140-290 Closed
Pembrolizumab Miscellaneous tumors HML 140-290 Closed
Pembrolizumab Prostate HML 140-290 Open
Pembrolizumab Upper-GI HML 140-290 Closed
Pembrolizumab Tumor-agnostic HML > 290 Closed
Regorafenib Adenoid cystic carcinoma BRAF mut Open
Regorafenib Duodenal FLT1 amp Open
Regorafenib Melanoma KIT mut Open
Regorafenib Esthesioneuroblastoma RET Open
Regorafenib NSCLC RAF1 mut Open
Regorafenib NSCLC RET Open
Regorafenib Thymus KIT mut Open
Ribociclib Anaplastic meningeoma CDKN2A loss/mut Closed
Ribociclib ACUP CDKN2A loss/mut Closed
Ribociclib Ceruminous adenocarcinoma CDKN2A loss/mut Closed
Ribociclib Ependymoma CDKN2A loss/mut Closed
Ribociclib Gastric cancer CDKN2A loss/mut Closed
Ribociclib Melanoma CDK4 amp Closed
Ribociclib Mesothelioma CDKN2A loss/mut Closed
Ribociclib Mucoepidermoid CDK6 amp Closed
Ribociclib Prostate CDKN2A loss/mut Closed
Ribociclib Salivary gland CDKN2A loss/mut Closed
Ribociclib Sarcoma CDKN2A loss/mut Closed
Ribociclib Thymus CDKN2A loss/mut Closed
Ribociclib Urinary tract CDKN2A loss/mut Closed
Rucaparib Mamma HRR alterations Open
Rucaparib Miscellaneous tumors HRR alterations Open
Rucaparib Ovarian HRR alterations Open
Rucaparib Pancreas HRR alterations Open
Rucaparib Prostate HRR alterations Open
Sunitinib Adenoid cystic carcinoma PDGFRA amp Open
Sunitinib Colorectal CSF1R mut Open
Sunitinib Colorectal FLT3 mut Open
Sunitinib Colorectal FLT3 amp Open
Sunitinib Mamma PDGFRB amp Open
Sunitinib NSCLC KIT amp Open
Sunitinib Osteosarcoma PDFGRB mut Open
Sunitinib Ovarian FGFR1 amp Open
Sunitinib Ovarian FGFR2 amp Open
Sunitinib Pancreas RET fusion Open
Sunitinib Pseudomyxoma peritonei FLT3 mut Open
Sunitinib Prostate PDFGRA mut Open
Sunitinib Thymus KIT mut Open
Sunitinib Thyroid cancer PDGFRA mut Open
Sunitinib Urinary tract FGFR1 amp Open
Talazoparib Tumor-agnostic ATM/ATR alteraties Open
Talazoparib Tumor-agnostic HRD signature Open
Trametinib ACUP MAP2K1 mut Open
Trametinib ACUP MAP3K1mut Closed
Trametinib Cervix MAP3K1mut Closed
Trametinib Cholangiocarcinoma MAP2K4 mut Closed
Trametinib Cholangiocarcinoma NRASmut Open
Trametinib Colorectal MAP2K4 mut Closed
Trametinib Colorectal MAP2K1 mut Open
Trametinib Glioneural tumor BRAF fusion Open
Trametinib Histiocytair sarcoma MAP2K1mut Open
Trametinib Mamma MAP3K1 mut Closed
Trametinib Mamma MAP2K4 mut Closed
Trametinib Melanocytic tumor GNA11 mut Open
Trametinib Neuroendocrine carcinoma MAP3K1 mut Closed
Trametinib NSCLC BRAF mut Open
Trametinib NSCLC BRAF fusion Open
Trametinib NSCLC MAP2K1 mut Open
Trametinib NSCLC NRAS mut Open
Trametinib Ovarian MAP2K4 mut Closed
Trametinib Ovarian NRAS mut Open
Trametinib Pancreas BRAF fusie Open
Trametinib Pancreas MAP2K1 mut Open
Trametinib Pancreas MAP2K4 mut Closed
Trametinib (Pilocytic) astrocytoma BRAF fusion Open
Trametinib Pleimorph tumor NRAS mut Open
Trametinib Prostate MAP3K1 mut Closed
Trametinib Prostate NRAS mut Open
Trametinib Salivary duct BRAF fusion Open
Trametinib Salivary duct NRAS mut Open
Trametinib Stomach cancer MAP2K1 mut Open
Trametinib Thyroid NRAs mut Open
Trametinib All tumor types GNAS mut Open
Trametinib All tumor types NF1 mut Open
Trametinib Urinary tract BRAF fusion Open
Trametinib Yolk sac tumor NRAS mut Open
Trastuzumab + pertuzumab Adenoid cystic carcinoma HER2 mut Open
Trastuzumab + pertuzumab Biliary tract HER2 amp Open
Trastuzumab + pertuzumab Cervix HER2 amp Open
Trastuzumab + pertuzumab Cervix HER2 mut Open
Trastuzumab + pertuzumab Colorectal HER2 amp Open
Trastuzumab + pertuzumab Colorectal HER2 mut Open
Trastuzumab + pertuzumab Duodenal HER2 amp Open
Trastuzumab + pertuzumab Hidradenocarcinoma HER2 amp Open
Trastuzumab + pertuzumab Melanoma HER2 amp Open
Trastuzumab + pertuzumab Neuroendocrine carcinoma HER2 amp Open
Trastuzumab + pertuzumab NSCLC HER2 amp Open
Trastuzumab + pertuzumab NSCLC HER2 mut Closed
Trastuzumab + pertuzumab Ovarian HER2 amp Open
Trastuzumab + pertuzumab Ovarian HER2 mut Open
Trastuzumab + pertuzumab Salivary duct HER2 amp Open
Trastuzumab + pertuzumab Sinosal carcinoma HER2 mut Open
Trastuzumab + pertuzumab Urinary tract HER2 amp Open
Trastuzumab + pertuzumab Urinary tract HER2 mut Open
Trastuzumab + pertuzumab Vulva HER2 amp Open
Vemurafenib + cobimetinib ACUP BRAF V600 mut Open
Vemurafenib + cobimetinib Erdheim Chester Disease BRAF V600 mut Open
Vemurafenib + cobimetinib NSCLC BRAF  V600E mut NSCLC Open
Vemurafenib + cobimetinib NSCLC BRAF  non-V600 mut Open
Vemurafenib + cobimetinib Papillair craniopharyngeoma BRAF V600 mut Open
Vemurafenib + cobimetinib Prostate BRAF non-V600 mut Open
Vemurafenib + cobimetinib Thyroid BRAF V600 mut Open
Vemurafenib + cobimetinib Ovarian BRAF V600 mut Open
Vemurafenib + cobimetinib Salivary duct BRAF V600 mut Open
Vismodegib Sarcoma PTCH1 mut Open
Vismodegib CNS tumors PTCH1 mut Open